Objectives. To define the potential role of cryosurgical ablation of the prostate (CSAP) as a treatment option for patients with localized prostate carcinoma (PCA), we performed a retrospective outcomes analysis of a large database of patients undergoing CSAP constructed from five institutions and compared this with matching outcomes from contemporary reports of patient outcomes after radiotherapy. Methods. A total of 975 patients who underwent CSAP as primary therapy from January 1993 to January 1998 with sufficient outcomes data available were identified. Patients were stratified into three groups on the basis of their clinical features. Biochemical-free survival (BFS), post-CSAP biopsy results, and post-CSAP morbidities were calculated and recorded. Results. The median follow-up for all patients was 24 months. The percentages of patients in the low, medium, and high-risk groups were 25%, 34%, and 41%, respectively. For prostate-specific antigen thresholds of less than 0.5 and less than 1.0 ng/mL, the 5-year actuarial BFS ranged from 36% to 61% and 45% to 76%, respectively, depending on the risk category. Overall, the positive biopsy rate was 18%. Morbidities included impotence in 93%, incontinence in 7.5%, rectourethral fistula in 0.5%, and transurethral resection of the prostate in 13% of patients (10% approved warming catheters versus 40% nonapproved). Conclusions. For each risk group, the 5-year BFS and positive biopsy rate after CSAP was comparable to matching outcomes reported after radiotherapy. Morbidities also seemed comparable, with impotence rates higher and rectal injury rates lower after CSAP than after radiotherapy. These data indicate that CSAP can be performed with low morbidity and can produce cancer-related results comparable to those reported for patients undergoing radiotherapy. UROLOGY 57: [518][519][520][521][522][523] 2001.
P
rostate adenocarcinoma (PCA) continues to be the most common malignancy and second most common cause of cancer-related death in American men. Despite the voluminous reports investigating this disease, defining a standard of treatment for individual patients who present with a new diagnosis of PCA remains problematic. Historically, the dominant treatment options for localized disease have included radical prostatectomy and external beam radiotherapy. More recently, particularly during the past 5 years, novel or modified treatments for localized PCA have been introduced, including ultrasound-guided interstitial brachytherapy, three-dimensional conformal radiotherapy, high-dose combination radiotherapy, HDR-iridium 192 brachytherapy, proton beam radiotherapy, high-intensity focused ultrasound thermotherapy, and cryoablation. In the absence of randomized prospective comparisons between any two of these approaches, recommendations for treatment must be made on the basis of the available information. Some of the principal problems with deriving treatment recommendations on the basis of published data are that patient selection may vary considerably among reports that provide post-treatment outcomes and that the definitions of success, particularly if surrogate outcomes were relied on, may vary as well.
During the past 5 years, a number of reports have been published documenting the results after the use of transrectal ultrasound-guided cryoablation of the prostate for patients with PCA, [1] [2] [3] and these reports are not immune from the problems mentioned above. A number of investigators have suggested very promising preliminary results with regard to cancer-related outcomes such as biochemical disease-free survival or negative biopsy rates, and others have raised concerns regarding the potential morbidities of this procedure and the feasibility of safely accomplishing whole-gland ablations.
In an effort to derive a more valid overview of the outcomes that might be anticipated for patients currently undergoing cryoablation, we conducted a retrospective pooled analysis from five institutions performing cryoablation during the past 5 years with stratified patient selection criteria and uniform definitions of cancer-related outcomes. Furthermore, the outcomes chosen were derived from similar or matching outcomes reported for radiotherapy studies to examine comparatively the relative role that cryoablation may currently have as a potential tool for treating patients with PCA.
MATERIAL AND METHODS

PATIENT SELECTION
The primary patient databases for all patients undergoing cryoablation at five institutions (New England Medical Center, University of California at San Francisco, Urologic Institute of New Orleans, Crittenton Hospital, and Alhambra Hospital) between 1993 and 1998 were submitted for pooled analysis. Excluded from the analysis were all patients with metastatic disease at the time of treatment and patients in whom previous radiation therapy had failed. Patients receiving any androgen deprivation therapy before cryoablation were identified and categorized separately. Therefore, the selection criteria consisted of all patients with clinical Stages T1 to T4, any PSA level, and any Gleason grade from each program.
RISK GROUPS
Patients were separated into three risk groups. The low-risk group was defined as patients with Stage T2a or lower, PSA 10.0 ng/mL or less, and Gleason grade 6 or less. The moderate risk group was defined as patients with any one of the following factors: Stage T2b or greater, PSA greater than 10.0 ng/mL, or Gleason grade 7 or greater. Finally, patients in the high-risk group were those having two or three of the above factors at the time of their procedure. These risk definitions are identical to those used in a recent report 4 and similar to others 5-7 documenting outcomes for patients undergoing various forms of contemporary radiotherapy.
PROCEDURE
For all patients, an attempt to ablate the entire prostate gland was made. In all cases, real-time transrectal ultrasound monitoring was used. However we did not stratify the procedures by the use of specific elements of cryotechnique. Aspects such as the number of cryoprobes (five to eight), number of freeze-thaw cycles/case (one to three), length of apical pullback, use of thermocouples for real-time temperature monitoring during freezing, and use of LN 2 or argon-based cooling systems varied among different institutions to a measurable degree. Consequently, for all patients examined in this study, a genuinely uniform treatment protocol was not used. All procedures typically took 2 to 3 hours, and patients were discharged with either suprapubic or urethral catheter drainage. These catheters were removed within 1 to 3 weeks or when spontaneous voiding (in the case of suprapubic tubes) resumed. After the CSAP procedure, PSA monitoring was maintained at regular but varying intervals among all institutions. After CSAP, 6 to 12 core biopsies were performed either at fixed intervals or in response to rising PSA levels. Post-treatment morbidities were identified by chart review and recorded.
STATISTICAL ANALYSIS
Actuarial analyses were performed by coding data on a caseby-case basis. Two criteria for success were used: maintenance of PSA at less than 0.5 ng/mL and maintenance of PSA at less than 1.0 ng/mL. Cases failing a given criterion of success were failed at the midpoint between the date of failure diagnosis and the date of the most recent preceding follow-up visit. Cases maintaining success criteria were censored at the date of the most recent follow-up visit. A separate actuarial curve was calculated for each biochemical success criterion. Nonparametric actuarial curves were generated from the resulting coded data using StatView (Statistical Analysis System Institute, Cary, NC). Additionally, two sets of stratified outcomes were created on the basis of preprocedural patient criteria. The first set was based on the three-point risk group variable. The second set stratified patients by whether they had undergone preoperative androgen ablation therapy. Curves were compared for statistical differences using the log-rank test. Analyses comparing population characteristic proportions were compared using the chi-square test. Table I . The median follow-up Ϯ SD for all patients was 24 Ϯ 16.5 months. Androgen deprivation was used for 3 to 8 months before the procedure in 30% of patients. Typically, it consisted of at least one luteinizing hormone-releasing hormone depot injection, with concomitant antiandrogen oral therapy administered on a random basis.
RESULTS
Patient characteristics are listed in
The 5-year actuarial biochemical-free survival (BFS) rates and positive biopsy rates for each risk group are listed in Table II and depicted in Figure  1 . Not surprisingly, BFS was dependent on the risk category. When patients were divided into those receiving neoadjuvant hormonal therapy and those not, surprisingly, improved BFS rates for both the 0.5 and 1.0 thresholds were seen in the nontreatment arm, 55% versus 40% and 69% versus 47%, respectively. However, a larger number of highrisk patients were segregated into the androgendeprivation group versus the non-androgen-deprivation group (49% versus 37%, P Ͻ0.0001). The crude positive biopsy rate was 18% among patients biopsied and 14% among all treated patients. The use of neoadjuvant hormonal therapy did not appear to alter the likelihood of avoiding positive biopsies. Table III lists the rates of four morbidities measured after CSAP. The use of nonapproved urethral warming catheters was associated with a significantly higher rate of urethral sloughing and slightly higher rates of incontinence and rectal fistulas.
COMMENT
The actuarial 5-year BFS rates for patients with PCA who undergo radiotherapy vary widely in published reports. This variance is a consequence of nonuniform patient selection, the use of varying dosing and techniques, and, especially, a lack of consensus on how best to define biochemical failure. Despite this lack of consensus, an overview of the radiotherapy data can be instructive.
After conventional (ie, nonconformal) external beam radiotherapy (6600 to 7000 cGy) for patients with Stage T1-T3 PCA, most reports note 5-year BFS rates ranging from 29% to 64%, 8, 9 depending on the criteria used, with rates of finding positive biopsies after radiotherapy ranging from 12% to 100%. 10 The overall 5-year BFS rates of 52% (PSA less than 0.5 ng/mL) and 63% (PSA less than 1.0 ng/mL) and overall positive biopsy rate of 18% noted in this series compares very favorably with these data. Results after more contemporary radiotherapy techniques are typically segregated by risk group. As shown in Table II , for patients with a low risk of progression undergoing brachytherapy and conformal radiotherapy (some with three-dimensional enhancement) the reported 5-year BFS rates were very similar, ranging from 75% to 87%, 6, [11] [12] [13] (brachytherapy) to 67% to 81% 4,6,7 (conformal radiotherapy), depending on the criteria used. For similar patients, we found a 5-year BFS rate of 76% using a PSA threshold of less than 1.0 ng/mL, which compares favorably with the above data.
For patients with higher risks of progression, 5-year BFS rates range from 0% to 60% 6,12,13 (brachytherapy) to 35% to 60% 4 -7 (conformal ra- FIGURE diotherapy), again depending on the criteria used.
Actuarial projections of overall biochemical-free survival stratified by risk categories for a PSA threshold of less than 1.0 for (A) patients without neoadjuvant hormonal therapy and (B) patients with neoadjuvant hormonal therapy. Numbers of patients in each group available for evaluation at 12-month intervals noted in parentheses.
In our series, we found that for patients with a medium risk of progression, the 5-year BFS rates were 67%, and for high-risk patients, 41%. Again, these results are very comparable to those noted after conformal radiotherapy techniques and appear to be superior to those reported for brachytherapy. The recent radiotherapy reports contain fewer data on post-treatment biopsy results, but several studies noted overall rates of positive biopsies ranging from 43% to 65%, 4,14,15 with a trend toward decreasing rates with dose escalation, especially for doses greater than 75 Gy. Very few data on positive biopsy results after brachytherapy are available, but two reports noted that among those low-risk patients who underwent biopsy, positive biopsies were seen in 22% to 26%. 11, 12 Our rates of 12% (low-risk) and 18% (overall) compare favorably with these findings.
The morbidities after radiotherapy vary among studies. 16 -28 Table III lists a comparison between the rates of four morbidities measured in the present study with those in published reports after radiotherapy. Broadly, significant differences appeared in the rates of erectile dysfunction and rectal injury between the two groups, with lower rates of rectal problems after CSAP but higher rates of potency after radiotherapy. The incidence of voiding dysfunction after CSAP was slightly higher as well, although a meaningful comparison was difficult without a uniform outcomes assessment vehicle for all groups.
Given that others have demonstrated the beneficial effects of androgen deprivation before cryotherapy in humans, 1 the observation of poorer PSA outcomes in the patients treated with androgen deprivation was unexpected. The best explanation for this finding is most likely that there was a statistically significant preponderance of higher risk patients in the treatment arm compared with the nontreatment arm. Prospective investigations, especially with stratified treatment protocols, should consider addressing this further.
Retrospective studies such as this one usually have a number of limitations inherent in the design. Perhaps most prominent in the present study is that genuinely direct comparisons with radiotherapy are impossible without the benefit of prospective randomization. However, the risk and outcome definitions in this report, although not matching precisely all the cited comparison radiotherapy studies, were fairly close. Also, using retrospective, physician-assessed rates of treatmentrelated morbidities may underestimate the rates that would be found using patient-derived outcomes assessment tools. However, we chose a relatively simple panel of treatment-related side effects to facilitate comparisons with similar data in the radiotherapy reports.
The cumulative experience during the past 5 years with CSAP supports several "critical elements" that seem necessary to maximize outcome. These include two freeze cycles, approved urethral warming, thermocouple monitoring, achieving temperatures of Ϫ40°C or less, and using six to eight cryoprobes per procedure. 1, 3, 29, 30 Although we were not able to stratify all patients in this study by actual technique, it was clear that only a small number were treated with all these features, making the pooled results reflective of a minimal treat- ment effect. One recent report noted that when all the above features were used, only a 2% positive biopsy rate was found. 30 The results from the present study indicate that even despite the variations in treatment technique, CSAP can achieve cancer-related outcomes that seem very comparable to similar or matching outcomes reported after radiotherapy. It is perhaps remarkable that the results seem to be reasonably similar despite a substantial disparity in resources and experience between the two therapies. It is conceivable that with only a modest increase in research/interest in CSAP that a uniformly effective technique might be developed, resulting in an even lower incidence of post-CSAP voiding dysfunction and even more reliable total prostatic ablation than was found in this report.
CONCLUSIONS
The data presented in this report suggest that CSAP can be a safe and effective treatment alternative for a significant number of patients with PCA. Future efforts designed to improve the current technique and to define clearly the mechanisms of effective in situ ablation of human prostatic tissue should be encouraged and broadly supported.
